<div id="readability-page-1"><div>By Katherine Hamilton Johnson &amp; Johnson's Rybrevant Faspro was approved as a treatment for people with lung cancer by the Food and Drug Administration. Rybrevant Faspro was approved across all indications for subcutaneous administration for patients with epidermal growth factor receptor-mutated non-small cell lung cancer, J&amp;J said Wednesday. The approval is based on the results of a Phase 3 trial, which met both co-primary pharmacokinetic endpoints. Patients treated showed longer duration of response, improved progression-free survival and longer overall survival. Rybrevant Faspro enables a simpler, shorter administration time for a first-line combination regime when combined with Lazcluze. Rybrevant is approved in the U.S. across four indications in that specific type of lung cancer. Write to Katherine Hamilton at katherine.hamilton@wsj.com (END) Dow Jones Newswires12-17-25 1920ET</div></div>

Johnson & Johnson's Rybrevant Faspro received FDA approval for treating epidermal growth factor receptor-mutated non-small cell lung cancer. The approval is based on successful Phase 3 trial results, showing improved survival rates and response duration. Rybrevant Faspro offers a simpler administration when combined with Lazcluze, and is approved for four indications in the U.S.

Johnson & Johnson Gets FDA Approval for Lung Cancer Treatment